Pages that link to "Q38191796"
Jump to navigation
Jump to search
The following pages link to Drugging the p53 pathway: understanding the route to clinical efficacy (Q38191796):
Displaying 50 items.
- Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy (Q26740191) (← links)
- Chemical Variations on the p53 Reactivation Theme (Q26749008) (← links)
- The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase (Q26749343) (← links)
- Gene aberrations for precision medicine against lung adenocarcinoma (Q26749348) (← links)
- Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies (Q26750639) (← links)
- Clinical Overview of MDM2/X-Targeted Therapies (Q26767402) (← links)
- Targeting Oncogenic Mutant p53 for Cancer Therapy (Q26770856) (← links)
- DDX3, a potential target for cancer treatment (Q26779054) (← links)
- Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors (Q26783710) (← links)
- Targeting the Checkpoint to Kill Cancer Cells (Q26795781) (← links)
- Mitochondria-Associated Endoplasmic Reticulum Membranes Microenvironment: Targeting Autophagic and Apoptotic Pathways in Cancer Therapy (Q26797284) (← links)
- Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer (Q26800059) (← links)
- Dysregulated transcriptional and post-translational control of DNA methyltransferases in cancer (Q26827297) (← links)
- Targeting the ubiquitin pathway for cancer treatment (Q26866185) (← links)
- Elucidation of Ligand-Dependent Modulation of Disorder-Order Transitions in the Oncoprotein MDM2 (Q27318807) (← links)
- Structural basis of how stress-induced MDMX phosphorylation activates p53 (Q27701526) (← links)
- The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer (Q28067196) (← links)
- The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target (Q28071415) (← links)
- Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment (Q28071935) (← links)
- The possibility of clinical sequencing in the management of cancer (Q28072144) (← links)
- Motif mediated protein-protein interactions as drug targets (Q28079554) (← links)
- JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress (Q28394074) (← links)
- Novel Pactamycin Analogs Induce p53 Dependent Cell-Cycle Arrest at S-Phase in Human Head and Neck Squamous Cell Carcinoma (HNSCC) Cells (Q28546975) (← links)
- Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas (Q28547093) (← links)
- New small molecules targeting apoptosis and cell viability in osteosarcoma (Q28547760) (← links)
- Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction (Q28550874) (← links)
- The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans (Q28601272) (← links)
- Restoration of tumor suppressor functions by small-molecule inhibitors (Q28830520) (← links)
- 53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration. (Q30786652) (← links)
- miR-600 inhibits cell proliferation, migration and invasion by targeting p53 in mutant p53-expressing human colorectal cancer cell lines (Q33599315) (← links)
- Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies (Q33610671) (← links)
- WIP1 phosphatase as pharmacological target in cancer therapy. (Q33720757) (← links)
- PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/β-catenin signaling pathway (Q33831066) (← links)
- The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cells (Q33905852) (← links)
- Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design. (Q33915380) (← links)
- MDM2 oligomers: antagonizers of the guardian of the genome (Q33922100) (← links)
- Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism (Q34079481) (← links)
- Small-molecule inhibitors of protein-protein interactions: progressing toward the reality (Q34263719) (← links)
- High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity (Q34274477) (← links)
- The re-emergence of natural products for drug discovery in the genomics era. (Q34459318) (← links)
- Optimization of the cyclotide framework to improve cell penetration properties (Q35063455) (← links)
- Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. (Q35087851) (← links)
- Wild type p53 reactivation: from lab bench to clinic. (Q35146343) (← links)
- Highly specific in vivo gene delivery for p53-mediated apoptosis and genetic photodynamic therapies of tumour (Q35196929) (← links)
- Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays (Q35397776) (← links)
- Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells. (Q35434111) (← links)
- Splicing function of mitotic regulators links R-loop-mediated DNA damage to tumor cell killing (Q35543181) (← links)
- Selective and potent proteomimetic inhibitors of intracellular protein-protein interactions (Q35555133) (← links)
- Targeted therapy in sarcomas other than GIST tumors (Q35622367) (← links)
- APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells (Q35667409) (← links)